- Home
- GNRC vs PCVX Comparison
GNRC vs PCVX Comparison
Compare GNRC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNRC | PCVX |
|---|---|---|
| Founded | 1959 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 7.0B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNRC | PCVX |
|---|---|---|
| Price | $187.02 | $59.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $211.75 | $88.25 |
| AVG Volume (30 Days) | 880.4K | ★ 927.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $4,209,147,000.00 | N/A |
| Revenue This Year | $17.36 | N/A |
| Revenue Next Year | $12.51 | N/A |
| P/E Ratio | $51.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $134.80 | $30.81 |
| 52 Week High | $296.44 | $65.00 |
Technical Indicators
Market Signals| Indicator | GNRC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.91 | 47.74 |
| Support Level | $135.53 | $58.51 |
| Resistance Level | $225.67 | $63.39 |
| Average True Range (ATR) | 7.19 | 2.10 |
| MACD | -0.42 | -0.39 |
| Stochastic Oscillator | 9.63 | 10.69 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.